Shares of Propanc Biopharma, Inc. (OTCMKTS:PPCB – Get Free Report) traded down 15.9% during mid-day trading on Wednesday . The company traded as low as $5.68 and last traded at $5.68. 432 shares changed hands during mid-day trading, an increase of 2% from the average session volume of 425 shares. The stock had previously closed at $6.75.
Propanc Biopharma Price Performance
The firm has a 50 day moving average price of $6.64 and a 200-day moving average price of $2.31.
Propanc Biopharma Company Profile
Propanc Biopharma, Inc, a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes.
Further Reading
- Five stocks we like better than Propanc Biopharma
- Using the MarketBeat Dividend Tax Calculator
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- How to Invest in Blue Chip Stocks
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- With Risk Tolerance, One Size Does Not Fit All
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
